Clinical Trials
24 trialsPhase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University
SLV-324 Treatment of Metastatic Solid Tumors
Solve Therapeutics
QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
Sir Run Run Shaw Hospital
Comparing Quality of Recovery Between ESPB and IV Lidocaine After Major Breast Cancer Surgery
Chinese University of Hong Kong
JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）
Shanghai Junshi Bioscience Co., Ltd.
TUSCANY
Aptose Biosciences Inc.
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC
Peking University
DGPR1008
The Affiliated Hospital of Qingdao University
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Vanderbilt-Ingram Cancer Center
A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China
Shanghai Junshi Bioscience Co., Ltd.
Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma
The Third Affiliated hospital of Zhejiang Chinese Medical University
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
The First Affiliated Hospital with Nanjing Medical University
Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement
Seoul National University
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
BGI, China
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
BGI, China
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
Mabwell (Shanghai) Bioscience Co., Ltd.
6MW3511 in Patients With Advanced Solid Tumor
Mabwell (Shanghai) Bioscience Co., Ltd.
Study of GDX012 in Patients With MRD Positive AML
GammaDelta Therapeutics Limited
A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm
Mabwell (Shanghai) Bioscience Co., Ltd.
Pharmacotherapy Personalization of Cancer Patients
Poznan University of Medical Sciences
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
Boehringer Ingelheim
HORIZON II
AstraZeneca